Advertisement
Screener

Capital Investment Advisors, LLC Historic Quarter Change: Foreign Stocks, Reduced

Capital Investment Advisors, LLC historic quarter change: Foreign Stocks, Reduced

In share positions in stocks (depositary receipts and foreign shares traded over the counter), over 21 quarters from 2013-12-31 to 2026-06-30, Capital Investment Advisors, LLC opened 16 positions, added to 39, reduced 40 and sold out of 16.

  • Q2 2026: Stock RIO; Country of operation —; Class SPONSORED ADR; Shares before 61,210.
  • Q1 2026: Stock RIO; Country of operation —; Class SPONSORED ADR; Shares before 64,717.
  • Q1 2026: Stock NVS; Country of operation —; Class SPONSORED ADR; Shares before 3,199.
  • Q4 2025: Stock RIO; Country of operation —; Class SPONSORED ADR; Shares before 69,515.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1582732), 21 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-06); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-04-17); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-01-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-10-23); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-07-15); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-04-14); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-01-13); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-10-17); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-07-12); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-04-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-10-18); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-07-20); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-04-14); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-01-11); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-10-28); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-07-27); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-04-29); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-05-05); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-10-24); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-07-30); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-04-29). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q2 2026RIO
RIO TINTO PLC
SPONSORED ADR61,21056,511-4,699$5,710,291$5,364,561-$345,7302026-08-06
Q1 2026RIO
RIO TINTO PLC
SPONSORED ADR64,71761,210-3,507$5,179,294$5,710,291+$530,9972026-04-17
Q1 2026NVS
NOVARTIS AG
SPONSORED ADR3,1993,121-78$440,998$476,679+$35,6812026-04-17
Q4 2025RIO
RIO TINTO PLC
SPONSORED ADR69,51564,717-4,798$4,588,679$5,179,294+$590,6152026-01-13
Q4 2025NVO
NOVO-NORDISK A S
ADR4,9074,745-162$272,277$241,428-$30,8492026-01-13
Q4 2025NVS
NOVARTIS AG
SPONSORED ADR3,5393,199-340$453,796$440,998-$12,7982026-01-13
Q4 2025BP
BP PLC
SPONSORED ADR12,33112,005-326$424,932$416,925-$8,0072026-01-13
Q1 2025RIO
RIO TINTO PLC
SPONSORED ADR97,00281,636-15,366$5,704,692$4,904,707-$799,9852025-04-14
Q1 2025NVS
NOVARTIS AG
SPONSORED ADR4,2034,014-189$408,947$447,427+$38,4802025-04-14
Q4 2024RIO
RIO TINTO PLC
SPONSORED ADR119,95897,002-22,956$8,537,387$5,704,692-$2,832,6952025-01-13
Q4 2024NVS
NOVARTIS AG
SPONSORED ADR4,2254,203-22$485,904$408,947-$76,9572025-01-13
Q4 2024TSM
TAIWAN SEMICONDUCTOR MFG LTD
SPONSORED ADS3,1453,125-20$546,161$617,077+$70,9162025-01-13
Q4 2024SHEL
SHELL PLC
SPON ADS11,26011,015-245$742,621$690,105-$52,5162025-01-13
Q4 2024BP
BP PLC
SPONSORED ADR12,75711,909-848$400,443$352,028-$48,4152025-01-13
Q3 2024RIO
RIO TINTO PLC
SPONSORED ADR401,950119,958-281,992$26,500,552$8,537,387-$17,963,1652024-10-17
Q3 2024BP
BP PLC
SPONSORED ADR13,66712,757-910$493,368$400,443-$92,9252024-10-17
Q3 2024SHEL
SHELL PLC
SPON ADS11,38811,260-128$821,982$742,621-$79,3612024-10-17
Q3 2024NVS
NOVARTIS AG
SPONSORED ADR4,6384,225-413$493,710$485,904-$7,8062024-10-17
Q1 2024RIO
RIO TINTO PLC
SPONSORED ADR400,362390,250-10,112$29,810,926$24,874,530-$4,936,3962024-04-15
Q1 2024TSM
TAIWAN SEMICONDUCTOR MFG LTD
SPONSORED ADS2,6862,369-317$279,365$322,244+$42,8792024-04-15
Q1 2024BP
BP PLC
SPONSORED ADR13,70513,486-219$485,148$508,152+$23,0042024-04-15
Q1 2024SHEL
SHELL PLC
SPON ADS11,59811,285-313$763,119$756,513-$6,6062024-04-15
Q2 2016ORANY
Orange Adr
FranceSPONSORED ADR24,00018,000-6,000$417,000$296,000-$121,0002016-07-20
Q2 2016NVS
Novartis A G Spon Adr
SPONSORED ADR4,0293,988-41$292,000$329,000+$37,0002016-07-20
Q1 2016TEVA
Teva Pharmaceutical
ADR18,09117,443-648$1,187,000$933,000-$254,0002016-04-14
Q1 2016ORANY
Orange Adr
FranceSPONSORED ADR30,00024,000-6,000$499,000$417,000-$82,0002016-04-14
Q1 2016NVS
Novartis A G Spon Adr
SPONSORED ADR4,0834,029-54$351,000$292,000-$59,0002016-04-14
Q4 2015TEVA
Teva Pharmaceutical
ADR18,18918,091-98$1,027,000$1,187,000+$160,0002016-01-11
Q4 2015NVS
Novartis A G Spon Adr
SPONSORED ADR4,0854,083-2$375,000$351,000-$24,0002016-01-11
Q4 2015ECTM
ECA Marcellus Trust
United StatesCOM UNIT26,49515,645-10,850$45,000$24,000-$21,0002016-01-11
Q3 2015TEVA
Teva Pharmaceutical
ADR18,49018,189-301$1,093,000$1,027,000-$66,0002015-10-28
Q3 2015NVS
Novartis A G Spon Adr
SPONSORED ADR4,1434,085-58$407,000$375,000-$32,0002015-10-28
Q2 2015TEVA
Teva Pharmaceutical
ADR19,58618,490-1,096$1,220,000$1,093,000-$127,0002015-07-27
Q2 2015ECTM
ECA Marcellus Trust
United StatesCOM UNIT35,85526,495-9,360$135,000$76,000-$59,0002015-07-27
Q1 2015ECTM
ECA Marcellus Trust
United StatesCOM UNIT38,25535,855-2,400$120,000$135,000+$15,0002015-04-29
Q1 2015NVS
Novartis A G Spon Adr
SPONSORED ADR3,9723,867-105$368,000$381,000+$13,0002015-04-29
Q3 2014TEVA
Teva Pharmaceutical
ADR19,78019,582-198$1,037,000$1,053,000+$16,0002014-10-24
Q2 2014TEVA
Teva Pharmaceutical
ADR20,17819,780-398$1,066,188,000$1,037,000-$1,065,151,0002014-07-30
Q2 2014NVS
Novartis A G Spon Adr
SPONSORED ADR3,9673,867-100$337,274,000$350,000-$336,924,0002014-07-30
Q1 2014ECTM
Egy East Cap Tr
United StatesCOM UNIT59,52553,975-5,550$457,000$480,378,000+$479,921,0002014-04-29

Similar Firms

Firm NameCountry13F ValueHoldings
GROUPAMA ASSET MANAGMENTFrance$6.847B395
PRINCIPAL SECURITIES, INC.United States$6.818B1,411
AIA Group LtdHong Kong$6.879B362
CANTOR FITZGERALD, L. P.United States$6.776B270
Crossmark Global Holdings, Inc.United States$6.769B1,239
Jericho Capital Asset Management L.P.United States$6.765B23
EDMOND DE ROTHSCHILD HOLDING S.A.Switzerland$6.914B973
CBRE INVESTMENT MANAGEMENT LISTED REAL ASSETS LLCUnited States$6.746B96
TOCQUEVILLE ASSET MANAGEMENT L.P.United States$6.744B547
HM PAYSON & COUnited States$6.932B1,600